Logo

Andelyn Biosciences and Armatus Bio Collaborate to Manufacture Gene Therapy for Charcot-Marie-Tooth Type 1A (CMT1A)

Share this
Andelyn Biosciences

Andelyn Biosciences and Armatus Bio Collaborate to Manufacture Gene Therapy for Charcot-Marie-Tooth Type 1A (CMT1A)

Shots:

  • Andelyn Biosciences and Armatus Bio have partnered to expedite the manufacturing of gene therapy for treating Charcot-Marie-Tooth Type 1A (CMT1A)
  • Under the terms of the agreement, Armatus will utilize Andelyn's expertise in adeno-associated virus (AAV) production and its proprietary suspension platform for the development activities, plasmid manufacturing, viral vector toxicology and GMP clinical manufacturing
  • The collaboration aims to increase the efficiency of the program and speed up the clinical studies of this precision method

Ref: Andelyn | Image: Andelyn

Related News:- SpliceBio Signs an Exclusive Collaboration and License Agreement with Spark Therapeutics to Develop Gene Therapy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions